Literature DB >> 8263847

Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.

E T Keller1, E G MacEwen, R C Rosenthal, S C Helfand, L E Fox.   

Abstract

Fifty-five dogs with lymphoma were treated using a doxorubicin-based sequential combination chemotherapy protocol. Complete response, partial response, and no response were seen in 46, 4, and 5 dogs, respectively. The overall median remission duration and survival times were 36 and 51 weeks, respectively. Age, sex, weight, World Health Organization stage, World Health Organization substage (i.e., a = not ill, b = ill), serum calcium concentration, blood urea nitrogen concentration, breed and protocol alteration secondary to toxicity were evaluated for prognostic significance. Univariate analysis of prognostic factors identified sex, World Health Organization substage, and serum calcium as statistically significant (P < or = .05) variables for both survival and remission duration. Upon multivariate analysis, only substage (P = .036) was a significant prognostic factor for remission duration, whereas, both substage (P = .006) and sex (P = .005) were significant prognostic factors for survival.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263847     DOI: 10.1111/j.1939-1676.1993.tb01021.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  30 in total

Review 1.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications.

Authors:  Daisuke Ito; Aric M Frantz; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2014-02-24       Impact factor: 2.046

2.  Canine acute leukaemia: 50 cases (1989-2014).

Authors:  A L Bennett; L E Williams; M W Ferguson; M L Hauck; S E Suter; C B Lanier; P R Hess
Journal:  Vet Comp Oncol       Date:  2016-07-12       Impact factor: 2.613

3.  Expression of O(6)-methylguanine-DNA methyltransferase causes lomustine resistance in canine lymphoma cells.

Authors:  Satoshi Kambayashi; Kouji Minami; Yuka Ogawa; Takehiro Hamaji; Chung Chew Hwang; Masaya Igase; Hiroko Hiraoka; Takako Shimokawa Miyama; Shunsuke Noguchi; Kenji Baba; Takuya Mizuno; Masaru Okuda
Journal:  Can J Vet Res       Date:  2015-07       Impact factor: 1.310

4.  The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.

Authors:  Melissa Parsons-Doherty; Valerie J Poirier; Gabrielle Monteith
Journal:  Can Vet J       Date:  2014-02       Impact factor: 1.008

5.  Factors associated with long-term survival in dogs undergoing liver lobectomy as treatment for liver tumors.

Authors:  Jessica R Kinsey; Stephen D Gilson; Joe Hauptman; Steve J Mehler; Lauren R May
Journal:  Can Vet J       Date:  2015-06       Impact factor: 1.008

6.  Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.

Authors:  J C Lori; T J Stein; D H Thamm
Journal:  Vet Comp Oncol       Date:  2010-09       Impact factor: 2.613

7.  Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.

Authors:  Cecile T Siedlecki; Philip H Kass; Martin J Jakubiak; Gillian Dank; Jarred Lyons; Michael S Kent
Journal:  Can Vet J       Date:  2006-01       Impact factor: 1.008

8.  Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.

Authors:  Shang-Lin Wang; Jih-Jong Lee; Albert Taiching Liao
Journal:  Can Vet J       Date:  2016-03       Impact factor: 1.008

9.  Preliminary evaluation of probiotic effects on gastrointestinal signs in dogs with multicentric lymphoma undergoing multi-agent chemotherapy: A randomised, placebo-controlled study.

Authors:  Maria C Jugan; Raelene M Wouda; Mary Lynn Higginbotham
Journal:  Vet Rec Open       Date:  2021-03-29

10.  Hypoxia inducible factor 1α expression and effects of its inhibitors in canine lymphoma.

Authors:  Satoshi Kambayashi; Masaya Igase; Kosuke Kobayashi; Ayana Kimura; Takako Shimokawa Miyama; Kenji Baba; Shunsuke Noguchi; Takuya Mizuno; Masaru Okuda
Journal:  J Vet Med Sci       Date:  2015-06-06       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.